Type 2 Diabetes
Conditions
Brief summary
High-protein (HP) diets are popular and evidence indicates they are more likely to be adhered to and produce more sustained weight loss, particularly under ad libitum conditions. They also improve glucose control and so may be helpful for treatment of Type 2 Diabetes (T2D), particularly in the short-term, possibly via an improvement in insulin secretion. Indeed, HP diets may be uniquely effective at promoting insulin secretion in T2D, but further research is needed to understand why HP. Thus, there is an urgent need to determine how HP diets affect T2D pathophysiology of insulin secretion and action using direct measures of β-cell dysfunction and insulin sensitivity. It is also imperative to know how the type of protein (animal vs. non-animal) affects insulin secretion in order to ultimately obtain an environmentally and economically sustainable HP diet that can improve glucose control and T2D pathophysiology in the long-term as well as providing patients with a greater choice for dietary management of T2D.
Interventions
OTHERDietary Intervention
Controlled dietary intervention; all food is provided to participants after being allocated to animal or non-animal dietary protein, for a duration of 5 weeks.
Sponsors
Marlow Foods Ltd
University of Exeter
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Aged 40-70 y * Body-mass index of 27-45 kg/m2 * Diagnosed with T2D with their most recent HbA1c value greater than 6.0% (\>43 mmol/mol) and receiving dietary advice and/or antidiabetic medication (metformin, DPP-4 inhibitors only). * Males and females
Exclusion criteria
* Habitual dietary intake of \<0.6 or \>1.2 g/kg/day protein (determined from dietary history interview given at screening) * Current use of insulin * HbA1c of 12% or more (≥108 mmol/mol) * Weight loss of more than 5 kg within the past 6 months * A recent estimated glomerular filtration rate (eGFR) of less than 30 mL/min, * Heart failure, * Participation in another clinical research trial, substance abuse, known cancer, myocardial infarction within the previous 6 months, current treatment with anti-obesity drugs, pregnancy or consideration of pregnancy, and hospital admission for depression or use of antipsychotic drugs.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Insulin sensitivity | Change from Baseline insulin sensitivity after 5-week controlled diet | Rate of disappearance (Rd) during the hyperinsulinaemic-euglycaemic clamp from participants on each diet, a measure of insulin sensitivity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| β-cell function | Change from Baseline β-cell function after 5-week controlled diet | β-cell function measured by modelling of glucose, insulin and c-peptide during MMTT |
| Glucose control | Change from Baseline glucose control after 5-week controlled diet | Glucose control measured by fasting glucose, 2 hour MMTT glucose, 24-hour glucose profile using continuous glucose monitoring probe and HbA1c. |
| Branched-chain amino acid (BCAA) metabolism | Change from Baseline BCAA after 1, 2, 3, 4 and 5 weeks of controlled diet | BCAA metabolism measured by plasma BCAA concentration. |
| Diabetes treatment satisfaction measured by the diabetes treatment satisfaction questionnaire | Change from Baseline treatment satisfaction after 5-week controlled diet | Treatment satisfaction measured by the diabetes treatment satisfaction questionnaire (DTSQ). |
Countries
United Kingdom
Outcome results
None listed